Andera Partners, a private equity firm, led a €60m Series B round in Tubulis, a biotechnology company, with participation from Evotec, Fund+, Bayern Kapital, BioMedPartners, coparion, High-Tech Gründerfonds, OCCIDENT and Seventure Partners. “This funding emphasizes that Tubulis is uniquely positioned to consolidate the findings of the last 20 years in the ADC field and translate this understanding into meaningful therapeutic benefits for patients. We have reached an important inflection point in the development of our platform technologies as well as our pipeline of highly novel protein-drug conjugates and we are now focused on unlocking new avenues in the treatment of solid tumors bringing safe and effective ADCs to patients. With this capital in place, we will execute on our growth strategy, including important focus areas for our pipeline and for how we can apply our proprietary technologies, biologic insights and new mechanisms of action to enable the true therapeutic value inherent in targeted therapeutics," Dominik Schumacher, Tubulis CEO and Co-Founder.